Multiple Myeloma Clinical Trials
M24-108
A Multicenter, Phase 1b, Open-label Study to Evaluate Dose Optimization Measures and Safety of ABBV-383 in Subjects with Relapsed or Refractory Multiple Myeloma.
M24-108
A Multicenter, Phase 1b, Open-label Study to Evaluate Dose Optimization Measures and Safety of ABBV-383 in Subjects with Relapsed or Refractory Multiple Myeloma.